The median duration of time from BC diagnosis to BM development and the median survival after BM were shorter in the HER-2-positive group than the HER-2-negative group, and the difference was statistically significant (20.4 vs. 37.7 months; p=0.017 and 5.3 vs. 11.1 months; p=0.014, respectively). Here, ERBB2 is linked to breast cancer.